Target Information

General Information of This Target (ID: PATR0CZQGR)
Target Name
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Gene Name
TLR7; TLR8
Gene ID
51284 ; 51311
Synonym 2
CD_antigen=CD288
Sequence 1
MVFPMWTLKRQILILFNIILISKLLGARWFPKTLPCDVTLDVPKNHVIVDCTDKHLTEIP
GGIPTNTTNLTLTINHIPDISPASFHRLDHLVEIDFRCNCVPIPLGSKNNMCIKRLQIKP
RSFSGLTYLKSLYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYLG
QNCYYRNPCYVSYSIEKDAFLNLTKLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKI
QEDDFNNLNQLQILDLSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSN
SLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELQVYRASM
NLSQAFSSLKSLKILRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQF
KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK
EASFMSVNESCYKYGQTLDLSKNSIFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP
LAELRYLDFSNNRLDLLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLQK
LMMNDNDISSSTSRTMESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISKN
SLSFLPSGVFDGMPPNLKNLSLAKNGLKSFSWKKLQCLKNLETLDLSHNQLTTVPERLSN
CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLL
HHNRFLCTCDAVWFVWWVNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNL
ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK
DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLENLSQSIQLSKKTVFVMTDK
YAKTENFKIAFYLSHQRLMDEKVDVIILIFLEKPFQKSKFLQLRKRLCGSSVLEWPTNPQ
AHPYFWQCLKNALATDNHVAYSQVFKETV

    Click to Show/Hide
Sequence 2
MENMFLQSSMLTCIFLLISGSCELCAEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQT
VGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGA
FLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWN
CYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEE
DFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLR
KINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINIS
RNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNL
EIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCA
AYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNN
RLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLT
DKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFL
NLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLS
HNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDI
GDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITT
MVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTFYDAYISYDTKDASVTDWVINE
LRYHLEESRDKNVLLCLEERDWDPGLAIIDNLMQSINQSKKTVFVLTKKYAKSWNFKTAF
YLALQRLMDENMDVIIFILLEPVLQHSQYLRLRQRICKSSILQWPDNPKAEGLFWQTLRN
VVLTENDSRYNNMYVDSIKQY

    Click to Show/Hide
Family
the Toll-like receptor family; the Toll-like receptor family
Function 1
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of uridine- containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs. Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction. In turn, the Myddosome signaling complex is formed involving IRAK4, IRAK1, TRAF6, TRAF3 leading to activation of downstream transcription factors NF-kappa-B and IRF7 to induce pro-inflammatory cytokines and interferons, respectively.

    Click to Show/Hide
Function 2
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of RNA degradation products specific to microorganisms that are initially processed by RNASET2. Recognizes GU-rich single- stranded RNA (GU-rich RNA) derived from SARS-CoV-2, SARS-CoV-1 and HIV- 1 viruses. Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction. In turn, the Myddosome signaling complex is formed involving IRAK4, IRAK1, TRAF6, TRAF3 leading to activation of downstream transcription factors NF- kappa-B and IRF7 to induce pro-inflammatory cytokines and interferons, respectively.

    Click to Show/Hide
Uniprot Entry
TLR7_HUMAN ; TLR8_HUMAN
HGNC ID
HGNC:15631 ; HGNC:15632
KEGG ID
hsa:51284 ; hsa:51311
Full List of The ADC Related to This Target
Phase 1 (discontinued)
Click To Hide/Show 1 ADC Related to This Stage
ADC Name Antibody Antigen Payload Linker ADC Info
GQ1007
Anti-HER2 antibody
Receptor tyrosine-protein kinase erbB-2 (HER2)
TLR7/8 agonist
Stable linker
ADC Info
Phase 2 (discontinued)
Click To Hide/Show 4 ADC Related to This Stage
ADC Name Antibody Antigen Payload Linker ADC Info
Trastuzumab imbotolimod [1]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
T785
BG based linker
ADC Info
ADC HE-S2 [2]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
Bifunctional immunomodulator D18
Disulfide linker 8
ADC Info
BDB-101 [3]
Undisclosed
Programmed cell death 1 ligand 1 (PD-L1)
TLR7/8 agonist
Undisclosed
ADC Info
PD-L1 ISA [4]
Undisclosed
Programmed cell death 1 ligand 1 (PD-L1)
TLR7/8 agonist
Undisclosed
ADC Info
Investigative
Click To Hide/Show 37 ADC Related to This Stage
ADC Name Antibody Antigen Payload Linker ADC Info
CD276 mAb-IMQ [5]
Hu276 mAb
CD276 antigen (CD276)
imiquimod
Phosphine-azide
ADC Info
Isumab01-C2a [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC25, Payload
Undisclosed
ADC Info
Isumab01-C2b [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC25, Payload
Undisclosed
ADC Info
Isumab01-C3 [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC23, Payload
Undisclosed
ADC Info
Isumab01-C6 [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC24, Payload
Undisclosed
ADC Info
Isumab04-C6 [6]
Undisclosed
Undisclosed
WO2025015586A1, ADC24, Payload
Undisclosed
ADC Info
Isumab01-C7 [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC34, Payload
Undisclosed
ADC Info
Isumab01-C8 [6]
Undisclosed
Folate receptor alpha (FOLR1)
WO2025015586A1, ADC35, Payload
Undisclosed
ADC Info
WO2023232144A1ADC23 [7]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC23, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC24 [7]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC24, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC25 [7]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC25, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC27 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC23, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC28 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC24, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC29 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC25, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC30 [7]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC25, Payload
SMCC
ADC Info
WO2023232144A1ADC31 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC25, Payload
SMCC
ADC Info
WO2023232144A1ADC34 [7]
mouse anti-human HER2 Ab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC34, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC35 [7]
mouse anti-human HER2 Ab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC35, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC36 [7]
mouse anti-human HER2 Ab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC34, Payload
SMCC
ADC Info
WO2023232144A1ADC37 [7]
mouse anti-human HER2 Ab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC35, Payload
SMCC
ADC Info
WO2023232144A1ADC38 [7]
Anti-mouse PD-L1 (B7-H1)
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC34, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC39 [7]
Anti-mouse PD-L1 (B7-H1)
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC35, Payload
Mc-Val-Cit-PABC
ADC Info
WO2023232144A1ADC40 [7]
Anti-mouse PD-L1 (B7-H1)
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC34, Payload
SMCC
ADC Info
WO2023232144A1ADC41 [7]
Anti-mouse PD-L1 (B7-H1)
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC35, Payload
SMCC
ADC Info
WO2023232144A1ADC42 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC34, Payload
SMCC
ADC Info
WO2023232144A1ADC43 [7]
Avelumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC35, Payload
SMCC
ADC Info
WO2023232144A1ADC44 [7]
Atezolizumab
Programmed cell death 1 ligand 1 (PD-L1)
WO2025015586A1, ADC35, Payload
SMCC
ADC Info
US20250025567A1 ExL1A1 [8]
anti-hCLDN6 antibody Ab1
Claudin-6 (CLDN6)
5-[ (4-{[ (2S)-2- (fluoromethyl)piperazin-1-yl]methyl}-2-methoxyphenyl)methyl|]-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine
3-Maleimidopropionic acid linker
ADC Info
US20250025567A1 ExL5A1 [8]
anti-hCLDN6 antibody Ab1
Claudin-6 (CLDN6)
US20250025567A1, ExlL5A1, Payload
Ethylmaleimide linker
ADC Info
US20250025567A1 ExL7A1 [8]
anti-hCLDN6 antibody Ab1
Claudin-6 (CLDN6)
US20250025567A1, ExlL7A1, Payload
3-Maleimidopropionic acid linker
ADC Info
US20250025567A1 ExL9A1 [8]
anti-hCLDN6 antibody Ab1
Claudin-6 (CLDN6)
US20250025567A1, ExlL7A1, Payload
3-Maleimidopropionic acid linker
ADC Info
CN113943310A ADC-11 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC25, Payload
Mc-Gly-Gly-Phe-Gly
ADC Info
CN113943310A ADC-12 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC25, Payload
CN113943310A, ADC-12, Linker
ADC Info
CN113943310A ADC-13 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC23, Payload
CN113943310A, ADC-12, Linker
ADC Info
CN113943310A ADC-16 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC24, Payload
CN113943310A, ADC-12, Linker
ADC Info
CN113943310A ADC-17 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC35, Payload
CN113943310A, ADC-12, Linker
ADC Info
CN113943310A ADC-18 [9]
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (HER2)
WO2025015586A1, ADC34, Payload
CN113943310A, ADC-12, Linker
ADC Info
References
Ref 1 Introduction to basic information on ADC drug trastuzumab imbotolimod.
Ref 2 Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021 Nov 11;64(21):15716-15726. doi: 10.1021/acs.jmedchem.1c00961. Epub 2021 Nov 3.
Ref 3 Seven and eight biopharmaceutical company produce pipeline
Ref 4 PD-L1-targeted ISAC combines myeloid cell activation, immune checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models; 2021
Ref 5 A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer
Ref 6 Antibody-drug conjugate compounds, and methods of use and treatment
Ref 7 Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
Ref 8 Antibody-drug complex containing Toll-like receptor 7/8 dual agonist compound
Ref 9 Deuterated camptothecin derivatives and their antibody-drug conjugates